Sana Biotechnology, Inc.
SANANASDAQHealthcareBiotechnology
Previous close
$3.91
+$0.17 · +4.55%
Pre-market
$3.86
−$0.05 · -1.28%
Aug 24, 5:13 AM ET
SANA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
51
Neutral
Sentiment
54
Mixed
Risk resilience
29
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Steven D. Harr
- Listed since
- Feb 4, 2021
- Employees
- 142
Market position
Day range
Current $3.91
52-week range
Current $3.91
- Open
- $3.79
- Previous close
- $3.74
- Volume
- 2.93M
- 0.86× average
- Average volume
- 3.42M
- Average daily volume
- Market cap
- 1.09B USD
- Beta
- 2.1
- Market reference 1
- 50-day average
- $3.4366
- +13.78% above average
- 200-day average
- $3.7033
- +5.58% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.04B USD
- P/E (TTM)
- -5.14×
- P/B (TTM)
- 7.48×
- P/S (TTM)
- 0×
- EV / EBITDA
- -4.48×
- Earnings yield
- -23.69%
- Free cash flow yield
- -14.05%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -151.77%
- Return on assets
- -58.57%
- Return on invested capital
- -54.08%
Financial health
- Debt / equity
- 0.48×
- Current ratio
- 1.89×
- Altman Z-score
- -5.49
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 12.75M USD | — | — | — | — |
| Gross profit | −12.75M USD | — | — | — | — |
| Research and development | 131.98M USD | 208.68M USD | 219.84M USD | 201M USD | 306.5M USD |
| Selling, general, and administrative | 44.3M USD | 64.04M USD | 73.3M USD | 71.56M USD | 50.41M USD |
| Operating expenses | 178.21M USD | 272.72M USD | 293.14M USD | 272.56M USD | 356.91M USD |
| Interest income | 3.85M USD | 10.47M USD | 9.94M USD | 3.76M USD | 676K USD |
| Depreciation and amortization | 12.75M USD | 17.39M USD | 24.56M USD | 15.63M USD | 11.07M USD |
| Operating income | −190.96M USD | −272.72M USD | −293.14M USD | −272.56M USD | −356.91M USD |
| Net income | −244.17M USD | −266.76M USD | −283.26M USD | −269.48M USD | −355.93M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 4 misses, 1 met estimate
- Average EPS surprise
- -12.04%
- 11 comparable reports
- Latest EPS result
- -0.22
- Estimate -0.15 · Miss by 49.76%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$8.67
121.74% upsidePrice history unavailable
High $12.00Average $8.67Low $7.00Recent analyst actions
SANA news
SANA peers
ETFs holding SANA
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI27.78M0.24%11.39B USD0.35%$165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI19.57M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM17.71M0.02%81.62B USD0.19%$299.96+0.77%
iShares Russell 2000 Growth ETFIWO6.29M0.04%15.16B USD0.24%$387.37+1.24%
Vanguard Extended Market ETFVXF6.09M0.01%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB5.02M0.05%10.75B USD0.44%$213.56+1.29%
Vanguard Russell 2000 ETFVTWO3.23M0.02%17.4B USD0.06%$121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA3.13M0.01%23.1B USD0.03%$34.83+0.52%State Street SPDR S&P Biotech ETFXBI- Market value
- 27.78M
- Weight
- 0.24%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 19.57M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 17.71M
- Weight
- 0.02%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
iShares Russell 2000 Growth ETFIWO- Market value
- 6.29M
- Weight
- 0.04%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
Vanguard Extended Market ETFVXF- Market value
- 6.09M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 5.02M
- Weight
- 0.05%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Russell 2000 ETFVTWO- Market value
- 3.23M
- Weight
- 0.02%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 3.13M
- Weight
- 0.01%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Continue in GoAI
Research SANAresearch.disclaimer